（1）以区间数进行业绩预告的 证券代码：301136 证券简称：招标股份 公告编号：2026-009 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 单位：万元 | 项 目 | | 本报告期 | | 上年同期 | | --- | --- | --- | --- | --- | | 归属于上市公 司股东的净利 | -1,260 | ～ | -630 | -611.05 | | 润 | | | | | | 扣除非经常性 | | | | | | 损益后的净利 | -1,900 | ～ | -950 | -1,416.9 | | 润 | | | | | 公司已就业绩预告有关事项与年报审计会计师事务所进行了预沟通，公司与 会计师事务所在本报告期的业绩预告方面不存在重大分歧。 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所 审计。 2、本报告期内，公司应收账款（合同资产）回款周期有所延长。为遵循谨慎 性原则，公司计提了坏账准备及商誉减值损失，影响本期经营业绩。 本报告期业绩预计亏损的主要原因如下： 1、本报告期内，公司业务承接量 ...

幸福蓝海影视文化集团股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 证券代码：300528 证券简称：幸福蓝海 公告编号：2026-001 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 （1）以区间数进行业绩预告的 单位：万元 | 项 | 目 | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 | | -16,200 | ～ | -12,600 | -19,245.59 | | 东的净利润 | | | | | | | 扣除非经常性损益 | | -19,000 | ～ | -14,900 | -24,522.83 | | 后的净利润 | | | | | | | 营业收入（如适 | | 73,000 | ～ | 93,000 | 65,391.92 | | 用） | | | | | | | 扣除后营业收入 | | 70,000 | ～ | 90, ...

扭亏为盈 同向上升 √同向下降 东莞宜安科技股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：300328 证券简称：宜安科技 公告编号：2026-011 号 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司 | 亏损：1,300万元-1,800万元 | 盈利：100.55万元 | | 股东的净利润 | | | | 扣除非经常性损 | 亏损：2,500万元-3,000万元 | 亏损：2,738.39万元 | | 益后的净利润 | | | 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所审计。 公司已就业绩预告有关事项与年报会计师事务所进行了预沟通，公司与会计师事务所 在本报告期的业绩预告方面不存在重大分歧。 三、业绩变动原因说明 一、本期业绩预计情况 （一）业绩预告期间：2025年1月1日-2025年12月31日 （二）业绩预告情况： （四）投资战略核心资产影响 报告期内，公司加大对新生产基地的投入，东莞铝镁合金生产基地 ...

Financial Projections - The company expects a net profit of between 2.8 million to 4.2 million CNY for the year 2025, representing a decline of 74.32% to 82.88% compared to the previous year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 1.6 million to 2.4 million CNY, reflecting a decrease of 80.60% to 87.07% year-on-year[5]. Profitability Challenges - The decline in profitability is attributed to changes in the overall market environment, industry policies, and shifts in retail structure and consumer behavior[4]. - Increased income tax expenses are due to the company's ineligibility for preferential tax rates under the Western Development policy, leading to higher tax liabilities[6]. - The company has terminated some loss-making projects, but residual costs from these projects continue to negatively impact current profits[6]. - The company has recognized impairment losses on goodwill based on the requirements of accounting standards for the fiscal year 2025[6]. Business Development - The company is in the early stages of developing new business areas, with ongoing R&D and market expansion costs that have not yet generated significant revenue[4]. Financial Reporting - The financial data presented is preliminary and has not been audited by the accounting firm, with detailed figures to be disclosed in the 2025 annual report[7].

Financial Performance - The company expects a net profit for 2025 to be positive but to decline by over 50% compared to the previous year [3] - Revenue for the reporting period is projected at approximately ¥197,090.55 million, representing an 8% decrease from ¥205,659.71 million in the same period last year [5] - Net profit attributable to shareholders is expected to be around ¥13,605.53 million, a decline of 55% from ¥18,140.71 million year-over-year [5] - The net profit after deducting non-recurring gains and losses is projected to be ¥11,390.44 million, down 58.38% from ¥15,925.62 million in the previous year [5] - The impact of non-recurring gains and losses on net profit is estimated to be approximately ¥22 million, compared to ¥28.65 million in the same period last year [8] Strategic Investments and Business Development - The company has increased strategic investments in the artificial intelligence sector and optimized its personnel structure by recruiting high-end talent in AI algorithm and product development [8] - The company is accelerating the cultivation of new businesses, although these new ventures are expected to contribute low revenue initially [8] Cash Flow and Client Management - Overall cash flow remains stable, but some clients have extended their payment cycles, leading to an increase in the provision for bad debts [7]

证券代码：920719 证券简称：宁新新材 公告编号：2026-001 (一)业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 (二)业绩预告情况 √年度净利润为负值 江西宁新新材料股份有限公司 2025 年年度业绩预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、本期业绩预告情况 三、风险提示 本次业绩预告为公司财务部门初步测算的结果，尚未经会计师事务所审计， 具体数据以公司 2025 年年度报告中披露的数据为准。 敬请广大投资者谨慎决策，注意投资风险。 江西宁新新材料股份有限公司 董事会 2026 年 1 月 30 日 单位：万元 | 项目 | | 本报告期 | | 上年同期 | 变动比例% | | --- | --- | --- | --- | --- | --- | | 归属于上市 ...

证券代码：000731 证券简称：四川美丰 公告编号：2026-04 三、业绩变动原因说明 （一）主营业务影响。报告期内，公司主营的化肥化工产品所 处行业新增产能释放，下游市场需求增速放缓。产品端：尿素、三 聚氰胺、硝酸铵、LNG 等主要产品市场价格持续下跌；成本端：复 合肥生产用主要原料市场行情总体呈攀升走势，价格中枢整体上移。 公司采取的应对举措：一是深耕市场布局，全力开拓客户资源，推 动部分主营产品销量实现同比增长；二是提升运营效率，全面落实 四川美丰化工股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况：预计净利润为负值 | 项 | 目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的净 利润 | | 亏损：9,800 | 万元–12,900 | 万元 | 盈利：27,173.78 | ...

证券代码：002082 证券简称：万邦德 公告编号：2026-007 万邦德医药控股集团股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 二、与会计师事务所沟通情况 本次业绩预告未经会计师事务所审计，公司已就业绩预告有关事项与会计 师事务所进行预先沟通，公司与会计师事务所在业绩预告方面不存在重大分歧。 三、业绩变动原因说明 1、公司受国家药品、医疗器械招标、集采政策持续推进的影响，集采覆 盖区域的进一步扩大，公司相关产品集采后价格下降明显，行业市场竞争加剧， 在第十批国家集采中有产品未能中标，造成公司利润大幅度下降。 2、公司由仿制药向创新药战略发展转型升级，加速创新药全球研发力度， 研发投入加大。 3、公司创新药国际化制剂车间、原料药基地、中非医疗科技园国际化标 准的器械车间投入大，投入使用的固定资产折旧增加，但尚未形成规模效应。 4、报告期内，高分子产品生产厂区整体异地搬迁，影响医疗器械产品的 生产与市场供应。 2 ...

Financial Performance Expectations - The company expects a net profit in the range of -12 million to -8 million RMB for 2025, representing a significant improvement of 92.86% to 95.24% compared to the previous year's net loss of 168.03 million RMB[5] - The net profit after deducting non-recurring gains and losses is projected to be between 5 million and 7.5 million RMB, marking an increase of 119.23% to 128.85% from a loss of 26 million RMB in the previous year[5] - The basic earnings per share are expected to be in the range of -0.015 to -0.010 RMB, compared to -0.21 RMB in the previous year[5] Operational Developments - The company’s subsidiary, Sinochem Dongda (Quanzhou) Co., Ltd., successfully launched a 240,000 tons/year polyether polyol project, contributing to partial profits during the reporting period[4] - The company has implemented refined management practices and strengthened its technical and marketing systems, leading to significant cost reduction and efficiency improvements[4] - The company is undergoing a site restoration project for certain land parcels, which has been publicly tendered, and the total restoration costs have been re-evaluated and accrued[4] Financial Reporting and Risk Awareness - The financial data in this earnings forecast has not been audited by the accounting firm, but preliminary discussions have been held without major discrepancies[3] - The company emphasizes the importance of investor awareness regarding investment risks associated with the preliminary earnings forecast data[6] - The reporting period for the earnings forecast is from January 1, 2025, to December 31, 2025[3] - The company will provide detailed financial data in its 2025 annual report[6]

Financial Performance - The company expects a net profit in the range of -5,000 to -3,000 thousand yuan, representing a year-on-year increase of 97.14% to 98.28% compared to the previous year's net profit of -17,465.34 thousand yuan[5]. - The net profit after deducting non-recurring gains and losses is projected to be between -18,000 and -12,000 thousand yuan, showing a year-on-year increase of 90.75% to 93.83% from -19,452.68 thousand yuan in the same period last year[5]. - The basic earnings per share are expected to be between -0.0099 and -0.0050 yuan, compared to -0.34 yuan in the previous year[5]. Operational Management - The company has implemented lean operational management in its medical sector, enhancing operational efficiency through process optimization and cost control measures[7]. - The company anticipates a significant reduction in goodwill impairment compared to 2024, where the impairment provision was 13,463.26 thousand yuan[8]. Earnings Forecast - The financial data presented is preliminary and has not yet been audited by the accounting firm, but there are no significant discrepancies reported[6]. - The company emphasizes the importance of cautious decision-making for investors due to the preliminary nature of the earnings forecast[9]. - The earnings forecast period is from January 1, 2025, to December 31, 2025[3]. - The company has communicated with the accounting firm regarding significant matters related to the earnings forecast[6]. Incentive Plan - The company did not meet the performance assessment trigger values for the 2023 restricted stock incentive plan for the year 2025, leading to a reversal of previously accrued share-based payment expenses[7].